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A B S T R A C T
Purpose: The objective of this study was to determine whether the adverse effects of antiepileptic-drugs
could be assessed by the eye movements of epilepsy patients.
Methods: This study was performed prospectively in a single tertiary hospital. The inclusion criteria for
this study were as follows: (1) consecutive patients with epilepsy taking antiepileptic-drugs regularly for
at least 1 year, (2) the absence of structural lesions on MRI, (3) an age 16 years old, (4) not using
medications that could inﬂuence eye movement, and (5) a normal neurological examination. The
latency, peak velocity and accuracy of the saccades and the gain of the pursuits were recorded by video-
based electro-oculography. We analyzed the differences in the parameters of the eye movements for 75
patients with epilepsy and 20 normal controls matched for age and sex.
Results: The total latency (1017.7  148.9 ms vs. 1150.7  106.6 ms, p = 0.0003) and accuracy [370.7% (95%
CI 364.1–376.4%, range 306–408.2%), 92.7% as total accuracy normalized value vs. 383.6% (95% CI 378.8–
398%, range 322.9–417.4%), 95.9% as total accuracy normalized value, p = 0.0005] were signiﬁcantly different
between the patients with epilepsy and normal controls. For the detection of nystagmus with video-based
electro-oculography, the clear cutoff values of total accuracy (388.7%, 97.2% as total accuracy normalized
value) revealed 93.4% sensitivity and 28.6% speciﬁcity, and the clear cutoff values of total latency
(1005.5 ms) showed 49.2% sensitivity and 78.6% speciﬁcity.
Conclusions: The total latency and accuracy of video-based electro-oculography may be screened to
identify patients with a high risk of adverse effects with antiepileptic-drugs.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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The primary concern with medical treatment using antiepilep-
tic drugs (AEDs) is that the response rate to AEDs has remained
unchanged. Although new AEDs have been introduced during the
last decade, at least one in three patients with epilepsy remains
resistant to AEDs [1–3]. Another obstacle to medical treatment
with AEDs is their adverse effects (AEs). At least 30% of patients
with epilepsy taking AEDs may suffer from AEs [3–5].
Because the majority of clinicians focus on achieving a seizure-
free state and tend to increase the dosage of AEDs, particularly in
patients with AED-resistant epilepsy, evaluating AEs in daily
clinical practice may be somewhat overlooked. AEs can be related
to both a poor quality of life and a poor response to treatment [5,6].
Furthermore, patients with epilepsy who are taking AEDs tend* Corresponding author. Tel.: +82 51 797 1195; fax: +82 51 797 1196.
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reto not voluntarily report their AEs, particularly in Asian cultures;
therefore, reliance an self-report of AEs may lead to a serious
underestimation of the true frequency of AEs in patients with
epilepsy.
The reporting of AEs can be increased by using standardized
questionnaires, such as an adverse event proﬁle (AEP) [6]. The AEP
consists of 19 items that include neurobiologically relevant
taxonomy [7]. In addition, a randomized control study showed
that the AEP has been a useful clinical tool, not only for detecting
AEs but also for improving the control of seizures and quality of life
[6]. However, both a patient’s depression and non-neurological
states, such as problems with the skin or mouth, can inﬂuence the
AEP scores [7–9].
The objectives of this study were as follows: (1) to determine
whether the AEs of AEDs could be assessed with eye movements
using video-based electro-oculography (VEOG) and (2) to compare
the sensitivity between the AEP and the parameters on the VEOG to
identify patients at a high risk of AEs.served.
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This study was performed prospectively in a single tertiary
hospital. The institutional review board approved this study. The
inclusion criteria for this study were as follows: (1) consecutive
patients with epilepsy who were taking AEDs regularly for at least
1 year, regardless of the use of mono-pharmacy or poly-pharmacy;
(2) the absence of structural lesions on MRI; (3) an age 16 years
old; (4) not taking any medications that could inﬂuence eye
movement, such as benzodiazepines; and (5) normal results on a
neurological examination, particularly the absence of nystagmus
or ataxia.
The movements of the left eye were recorded using a high-
resolution infrared scleral reﬂectance technique (SLVNG, SLMED
Inc.). The visual stimulus was a white square target on a dark–blue
background. The subjects were seated in a darkened room, and the
calibration was performed 20 s before the start of eye movement
recording. Spontaneous nystagmus with or without optic ﬁxation
was recorded in both the horizontal and vertical planes. The
saccades were generated by asking the subjects to follow a ﬁxed
and randomized target with ranges of 30.08 on the horizontal
plane. The latency, peak velocity, and accuracy were recorded for each
saccade. The latency was the time delay from the target moving to the
saccade onset, the peak velocity was the maximum velocity during an
eye movement, and the accuracy was computed using the following
equation: saccadic accuracy (%) = (amplitude of the initial saccade/
target amplitude)  100. The stimulus for smooth pursuit was a
moving target in a sinusoidal pattern with frequencies of 0.2 Hz and
0.4 Hz on the horizontal plane. The gain was computed for each
pursuit, which was calculated using the following equation: pursuit
gain = peak velocity of eye movement/peak velocity of target.
Each instance of latency, velocity and accuracy, with both the
ﬁxed and random objects, were summed and expressed as the total
latency (TL), total velocity (TV) and total accuracy (TA). The units
for TL and TV were millisecond, and the unit for TA was a
percentage. In addition, TA was also expressed as TAnormalized value
(dividing by 4, i.e., random and ﬁxed accuracy in right and left side)
for 100% as the base value. The references of TL, TV and TA were
obtained from 20 normal controls matched for age and sex.
The clinical variables recorded at the time of the VEOG included
age, duration of exposure to AEDs, AEP score, Beck depression
inventory (BDI) score, dosage and number of AEDs, AED-resistance,
types of seizures and presence of nystagmus on the VEOG. AED-
resistance was deﬁned as the failure of the adequate trials of two
tolerated, appropriately selected and used AEDs, to achieve
sustained freedom from seizures [10]. The dosage of AEDs was
standardized for the AED load. The AED load was deﬁned as the
sum of the prescribed daily dose/deﬁned daily dose for each
patient, in which the deﬁned daily dose corresponded to the
assumed average maintenance daily dose of a drug used for its
primary indication [11].
The primary endpoint for this study was the differences in the
parameters on the VEOG between the 75 consecutive patients with
epilepsy and the 20 normal controls matched for age and sex. In
addition, we analyzed the possible correlations between the
clinical variables and the parameters on the VEOG.
We analyzed the parameters on the VEOG and the clinical
variables using Fisher’s exact test or the chi-squared test for
categorical variables and Student’s t-test or the Mann–Whitney U
test for numerical variables according to their distribution. Of the 75
consecutive patients, we found 14 patients with nystagmus on
VEOG only. These 14 patients were normal on their neurological
examinations and did not complain of any AEs, including dizziness.
To evaluate the sensitivity and speciﬁcity for detecting nystagmus
on the VEOG, we analyzed the clear cutoff values with the receiver
operating characteristic curve (ROC). We compared the sensitivityand speciﬁcity of the clear cutoff values between the AEP and VEOG
for detecting nystagmus. All statistical tests were performed using
MedCalc1 (MedCalc Software version 13, Ostend, Belgium). The
categorical variables were presented as the frequency and the
percentage. The numerical variables with normal distributions were
presented as the mean  standard deviation, and those without
normal distributions were described as the median with the 95%
conﬁdence interval and range. A p value <0.05 was considered
statistically signiﬁcant. We set a p value <0.017 (0.05/3) as signiﬁcant
when comparing the parameters, TL, TV and TA, on the VEOG between
the patients and controls with multiple corrections.
3. Results
3.1. Demographics of the patients and controls
Seventy-ﬁve epilepsy patients met the inclusion criteria, and 20
healthy volunteers were used as the normal controls who were
matched for age and sex. The mean age of the patients was
38.4  11.9 years old, and that of the controls was 38.9  14.9 years
old (case vs. control, p = 0.8). Twenty-nine of the 75 patients were
male, whereas 10 patients were male in the controls (case vs. control,
p = 0.5). The median age of the onset of epilepsy was 23.5 years old
(95% CI 19–28.5 years old, range 6–67 years old), and the duration of
exposure to AEDs was 124  112 months. AED-resistance was found
in 21% (16/75), whereas 79% (59/75) had well-controlled epilepsy.
Partial seizures were noted in 88% (66/75), and 12% (9/75) had
generalized seizures. Forty-six patients were on 1 AED, whereas 29
patients were on poly-pharmacy, of whom 19 patients were taking
two AEDs and 10 patients were taking three AEDs. Fifty-seven
patients were taking at least one AED with a sodium channel blocker,
such as carbamazepine, lamotrigine, phenytoin, or oxcarbazepine,
two patients were taking two different AEDs with a sodium
channel blocker and 16 patients were taking no AEDs with a sodium
channel blocker. The median AED load was 0.9 (95% CI 0.8–1.07, range
0.33–6.33).
3.2. Difference in the parameters on the VEOG between patients with
epilepsy and controls
There were signiﬁcant differences in the VEOG parameters
between the 75 patients with epilepsy and the 20 controls
(Table 1). The parameters in the pursuits were not different
between the groups; however, both the TL and TA were
signiﬁcantly different between the groups after multiple correc-
tions. Both the TL (1017.7  148.9 ms vs. 1150.7  10 6.6 ms,
corrected p = 0.0003) and TA [370.7% (95% CI 364.1–376.4%, range
306–408.2%), 92.7% as TAnormalized value vs. 383.6% (95% CI 378.8–
398%, range 322.9–417.4%), 95.9% as TAnormalized value, corrected
p = 0.0005] were signiﬁcantly decreased in the patients with epilepsy,
but not in the controls. These signiﬁcant differences in the latency and
accuracy remained after stratiﬁcation of the ﬁxed and random
saccadic movements. However, the presence of nystagmus on the
VEOG did not inﬂuence either the TL (1055.6  104.4 ms with
nystagmus on the VEOG vs. 1009  156.7 ms without nystagmus on
the VEOG, corrected p = 0.29) or the TA [371.3% (95% CI 352.9–389.7%,
range 333.4–399.9%), 92.8% as TAnormalized value with nystagmus on
the VEOG vs. 370.7% (95% CI 364–377.3%, range 306.1–408.2%), 92.7%
as TAnormalized value without nystagmus on the VEOG, corrected
p = 0.86].
In addition, there were positive correlations between the TL and
age (r = 0.22, p = 0.03) and the duration of exposure to AEDs
(r = 0.25, p = 0.08). However, the AEP scores, the AED load, and the
number of AEDs were not correlated with the TL (Table 2). We were
also unable to identify any relationship between the clinical
variables and the TA.
Table 1
Parameters on video-based electro-oculography between patients and controls.
Normal controls Patients using AEDs p
Saccade
Fixed velocity (ms) 892.2 (95% CI 841.4–1059.1, range 658.6–1235) 879.2 (95% CI 795–959, range 323–2075.1) 0.2
Fixed accuracy (%) 193.1  12.3 182  14.3 0.002
Fixed latency (ms) 536  69.2 468  93.6 0.0029
Random velocity (ms) 970.9 (95% CI 877.7–1075.5, range 643.9–1383.2) 877.9 (95% CI 822.7–953.2, range 736.7–1017.9) 0.08
Random accuracy (%) 192.8 (95% CI 189.1–199.2, range 160–206) 185.6 (95% CI 182.9–189.3, range 129–209) 0.003
Random latency (ms) 620.9 (95% CI 572.2–666.6, range 500.9–714.3) 558.7 (95% CI 537.8–583.4, range 513.4–606.7) 0.001
Total velocity (ms) 1894.6 (95% CI 1698.4–2156.8, range 1302.6–2505.6) 1751.3 (95% CI 1587.3–1918.6, range 958.7–3600.8) 0.13
Total accuracy (%) 383.6 (95% CI 378.8–398, range 322.9–417.4), 95.9%
as TAnormalized value
370.7 (95% CI 364.1–376.4, range 306–408.2), 92.7%
as TAnormalized value
0.0005
Total latency (ms) 1150.7  106.6 1017.7  148.9 0.0003
Pursuit
0.2 Hz gain 2.0 (95% CI 1.8–2.2, range 1.4–2.6) 1.8 (95% CI 1.8–1.9, range 0.5–3.5) 0.12
0.4 Hz gain 1.8 (95% CI 1.6–1.9, range 1.0–2.4) 1.7 (955 CI 1.6–1.8, range 0.8–3.2) 0.25
Total gain 3.8 (95% CI 3.5–4.0, range 2.6–5.1) 3.4 (955 CI 3.3–3.7, range 1.3–6.7) 0.17
AEDs: antiepileptic drugs; TA: total accuracy.
Table 3
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according to the epilepsy status because the signiﬁcant differences
found in this study might be inﬂuenced by the epilepsy itself rather
than by the effects of the AEDs. We found that a status of severe
epilepsy (AED-resistant epilepsy) did not affect the parameters.
The TL in severe epilepsy was 1033.2  207.1 ms and the TL in non-
severe epilepsy was 1013.5  130.8 ms (corrected p = 0.64). The TA in
severe epilepsy was 365.5% [(95% CI 355.0–380.5%, range 306.1–
396.6%), 91.4% as TAnormalized value] and the TA in non-severe epilepsy
was 371.2% [(95% CI 365.9–377.2%, range 308.5–408.2%), 92.8% as
TAnormalized value, corrected p = 0.42]. Additionally, the types of
seizures did not impinge on the parameters. The TL for the partial
seizures was 1014  151.2 ms and the TL for the generalized seizures
was 1045  135.3 ms (corrected p = 0.55). The TA in the partial
seizures was 370.7% (95% CI 363.6–376.7%, range 306.1–402.4%),
92.7% as TAnormalized value and the TA in the generalized seizures was
370.7% [(95% CI 342.2–384.7%, range 335.5–408.2%), 92.5% as
TAnormalized value, corrected p = 0.87]. Additionally, we failed to ﬁnd
a difference of parameters between the number of AEDs. The TL in
the mono-pharmacy was 1007.7  141.7 ms and the TL in the poly-
pharmacy was 1033.6  160.9 ms (corrected p = 0.46). The TA in the
mono-pharmacy was 370.9% (95%CI 363.6–377.9, range 308.5–
408.2), 92.7% as TAnormalized value and the TA in the poly-pharmacy
was 369.8% [(95%CI 360–378.2, range 306.1–396.6), 92.5% as
TAnormalized value, corrected p = 0.76]. There was a trend of increasing
TL and TA as sodium channel blockers were added, but this was not
statistically signiﬁcance (p = 0.072 for TL, p = 0.35 for TA).
3.3. Comparison of the AEP with the VEOG parameters
Of the 75 patients with epilepsy, 14 patients showed nystagmus
only on the VEOG. None of the 14 patients complained of any AEs,
including dizziness, and were normal on their neurological
examinations, whereas none of the 20 normal controls showedTable 2









Exposure 0.25 0.08 0.16 0.28
Age 0.22 0.03 0.12 0.26
Onset 0.03 0.85 0.17 0.24
AEP 0.1 0.3 0.02 0.8
AED load 0.02 0.8 0.02 0.8
AED number 0.09 0.8 0.02 0.8
AEP: adverse event proﬁle; AEDs: antiepileptic drugs.nystagmus on the VEOG. We also analyzed the sensitivity and
speciﬁcity between the AEP and the VEOG for detecting nystag-
mus. The ROC curve analysis showed that the clear cutoff values of
the TA (388.7%, 97.2% as TAnormalized value) and the TL
(1005.5 ms) revealed 93.4% sensitivity and 28.6% speciﬁcity,
respectively, and 49.2% sensitivity and 78.6% speciﬁcity for
detecting nystagmus on VEOG, respectively. When using the clear
cutoff value of the AEP score (AEP > 40) for detecting nystagmus,
the sensitivity was only 39.3% and the speciﬁcity was 78.6%. The
sensitivity of both the TA and the TL was signiﬁcantly higher in the
VEOG than the AEP for detecting nystagmus (Table 3).
4. Discussion
The primary ﬁnding of this study is that AEDs can affect saccades.
Previous studies also support our ﬁndings, but those studies were
performed in healthy volunteers and compared the effects between
AEDs [12–18]. This study is the ﬁrst systematic approach to
determine whether the AEs of AEDs can be assessed using the eye
movements obtained with VEOG. We used very strict criteria for
this study, and included only patients with no structural lesions
and no medications that might inﬂuence saccades. Additionally, the
patients for this study were normal upon neurological examinations
and did not report any clinical AEs, such as dizziness.
We compared the VEOG parameters of the patients with
epilepsy with the controls and found that the TL and the TA were
signiﬁcantly different between the groups, even after multiple
corrections. A possible explanation of this signiﬁcant difference
may be the effects of epilepsy itself rather than the AEDs. Epilepsy
is a pathological condition in the brain, and this pathology may
alter the structures in the brain involving saccades. If epilepsy
impinges on saccades, the parameters of saccades would beSensitivity and speciﬁcity of video-based electro-oculography and adverse event
proﬁle for detecting nystagmus.
Cutoff value Sensitivity (%) Speciﬁcity (%)
Exposure to AEDs




High risk with nystagmus




AEP > 40 39.30 78.60
AEDs: antiepileptic drugs; TA: total accuracy; AEP: adverse event proﬁle.
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expect a dose-response in saccades, such that the more severe
the epilepsy, the more disturbed the parameters of saccades. In
addition, we found that the parameters did not differ according to
the epilepsy status, such as intractability or type of seizures.
Furthermore, we included only patients who had negative MRIs
and who were not on medications that might inﬂuence saccades.
Based on our ﬁndings, a reasonable explanation for the differences
in the parameters of the VEOG may be because of the effects of the
AEDs rather than the epilepsy itself.
Although a decreased TA is a reasonable consequence of AED use,
a decreased TL was not expected. Many studies revealed that latency
was prolonged with AEDs [12–14,17,18], whereas other studies did
not obtain this result [16]. It is difﬁcult to explain why both the TL
and the TA were signiﬁcant parameters and why the TL was
decreased in patients with AEDs, whereas the TV did not differ from
the controls. The complicated networks within the brain, including
various parts of the cerebral cortex, the superior colliculus and
brainstem, with modiﬁcations by the cerebellum and the basal
ganglia, are required to generate saccades [19]. Recent studies
provided indirect evidence that suggests the important roles of ion
channels, particularly calcium channels, sodium channels and GABA
receptors, in the generation of saccades [20–23]. The mechanisms by
which the majority of AEDs act is on ion channels or GABA receptors
[24]. These mechanisms may contribute to the development and
effects of AEs caused by AEDs. The neurons involved in the control of
saccades in the brain also exert their physiological roles through ion
channels or GABA receptors. AEDs may block the inhibitory inter-
neurons in addition to the excitatory neurons, and the neurons
involved in the control of saccades may be disinhibited, resulting in
decreased TL in patients taking AEDs.
Another important ﬁnding of this study is that speciﬁc clear
cutoff values on the VEOG may identify patients who are at a high
risk of AEs from AEDs, even though they do not complain of AEs. In
this study, we found that the 14 patients who showed nystagmus on
VEOG only did not complain of any AEs, including dizziness, and had
normal neurological examinations. The presence of nystagmus is a
very reliable neurological sign indicating the presence of AEs from
AEDs. These 14 patients may be high-risk patients for developing
AEs at any time. This clinical situation requires the identiﬁcation of
patients who are at a high risk for AEs, whether using a standardized
questionnaire or biomarker. Because AEP is a good instrument for
identifying patients with AEs, we compared the sensitivity and
speciﬁcity between the AEP score with the parameters on VEOG to
identify high risk-patients. The sensitivity of the parameters on
VEOG was higher than the AEP score. When setting the clear cutoff
values of TA (388.7%), the sensitivity was 93.4% for detecting
nystagmus on the VEOG. AEP scores are inﬂuenced by depression
and a non-neurological status, such as problems with the skin or
mouth, whereas the parameters on VEOG may more directly reﬂect
the status of the brain under the inﬂuence of AEDs.
This study has limitations. First, the population for this study
was limited to subjects with epilepsy without structural lesions.
We are unable to use the signiﬁcant parameters of the VEOG in
cases of patients who have structural lesions or are taking
medications that affect saccades. The neurons controlling saccades
may be inﬂuenced by structural lesions that are responsible for
epilepsy, which may decrease the clinical utility VEOG for
monitoring AEs. Second, although the neurons involved in the
control of saccades may be disinhibited, resulting in a decreased
TL in the patients using AEDs, we must conﬁrm our results,
particularly the decrease in TL in the patients with AEDs. Third, we
did not analyze the serum concentrations of the AEDs. It is possible
that the serum concentration of the AEDs may be related to the
parameters on VEOG. A future study that focuses on the serum
concentration of AEDs and the parameters of saccades is necessary.5. Conclusions
The total latency and accuracy on video-based electro-
oculography may be used to screen and identify patients with a
high risk of adverse effects to antiepileptic drugs.
Conﬂict of interest statement
None of the authors has any conﬂicts of interest to disclose.
References
[1] Kwan P, Brodie MJ. Early identiﬁcation of refractory epilepsy. N Engl J Med
2000;342:314–9.
[2] Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med
2011;365:919–26.
[3] Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy:
pursuing seizure freedom and tolerability in adults. Curr Opin Neurol
2012;25:164–72.
[4] Brodie MJ. Meta-analyses of antiepileptic drugs for refractory partial (focal)
epilepsy: an observation. Br J Clin Pharmacol 2013;76:630–1.
[5] Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol
2012;11:792–802.
[6] Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic
screening allows reduction of adverse antiepileptic drug effects: a randomized
trial. Neurology 2004;62:23–7.
[7] Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects:
toward a clinically and neurobiologically relevant taxonomy. Neurology
2009;72:1223–9.
[8] Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, et al.
Relationship between adverse effects of antiepileptic drugs, number of copre-
scribed drugs, and drug load in a large cohort of consecutive patients with
drug-refractory epilepsy. Epilepsia 2010;51:797–804.
[9] Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA, et al.
Determinants of health-related quality of life in pharmacoresistant epilepsy:
results from a large multicenter study of consecutively enrolled patients using
validated quantitative assessments. Epilepsia 2011;52:2181–91.
[10] Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, AllenHW, Mathern G, et al. Deﬁnition
of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE
Commission on Therapeutic Strategies. Epilepsia 2010;51:1069–77.
[11] Deckers CL, Hekster YA, Keyser A, Meinardi H, Renier WO. Reappraisal of
polytherapy in epilepsy: a critical review of drug load and adverse effects.
Epilepsia 1997;38:570–5.
[12] Remi J, Huttenbrenner A, Feddersen B, Noachtar S. Carbamazepine but not
pregabalin impairs eye control: a study on acute objective CNS side effects in
healthy volunteers. Epilepsy Res 2010;88:145–50.
[13] Blau PA, Schwade N, Roland P. Diazepam tolerance effects on vestibular
function testing, Part I: Saccadic parameters during electronystagmography.
Ann Otol Rhinol Laryngol 2005;114:621–8.
[14] Noachtar S, von Maydell B, Fuhry L, Buttner U. Gabapentin and carbamazepine
affect eye movements and posture control differently: a placebo-controlled
investigation of acute CNS side effects in healthy volunteers. Epilepsy Res
1998;31:47–57.
[15] Zaccara G, Gangemi PF, Messori A, Parigi A, Massi S, Valenza T, et al. Effects of
oxcarbazepine and carbamazepine on the central nervous system: compu-
terised analysis of saccadic and smooth-pursuit eye movements. Acta Neurol
Scand 1992;85:425–9.
[16] Ball DM, Glue P, Wilson S, Nutt DJ. Pharmacology of saccadic eye movements in
man 1. Effects of the benzodiazepine receptor ligands midazolam and ﬂuma-
zenil. Psychopharmacology (Berl) 1991;105:361–7.
[17] Masson GS, Mestre DR, Martineau F, Soubrouillard C, Brefel C, Rascol O, et al.
Lorazepam-induced modiﬁcations of saccadic and smooth-pursuit eye move-
ments in humans: attentional and motor factors. Behav Brain Res
2000;108:169–80.
[18] Zwanzger P, Schule C, Eser D, Baqhai TC, Padberq F, Ella R, et al. Saccadic eye
velocity after selective GABAergic treatment with tiagabine in healthy volun-
teers. Neuropsychobiology 2005;52:147–50.
[19] Lo C, Shorvon SD, Luxon LM, Bamiou DD. Saccadic eye movements and anti-
epileptic drugs. Epilepsy Res 2008;78:93–101.
[20] Subramony SH, Schott K, Raike RS, Callahan J, Lanqfor LR, Christova PS, et al.
Novel CACNA1A mutation causes febrile episodic ataxia with interictal cere-
bellar deﬁcits. Ann Neurol 2003;54:725–31.
[21] Goffart L, Chen LL, Sparks DL. Deﬁcits in saccades and ﬁxation during muscimol
inactivation of the caudal fastigial nucleus in the rhesus monkey. J Neurophy-
siol 2004;92:3351–67.
[22] Lucas PT, Meadows LS, Nicholls J, Ragsdale DS. An epilepsy mutation in the
beta1 subunit of the voltage-gated sodium channel results in reduced channel
sensitivity to phenytoin. Epilepsy Res 2005;64:77–84.
[23] Kaneko CR, Fuchs AF. Effect of pharmacological inactivation of nucleus reti-
cularis tegmenti pontis on saccadic eye movements in the monkey. J Neuro-
physiol 2006;95:3698–711.
[24] French JA, Gazzola DM. Antiepileptic drug treatment: new drugs and new
strategies. Continuum (Minneap Minn) 2013;19:643–55.
